Creo Medical Group (LON:CREO) Sets New 1-Year Low – What’s Next?

Creo Medical Group PLC (LON:CREO)’s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 14.25 ($0.18) and last traded at GBX 14.50 ($0.19), with a volume of 364450 shares trading hands. The stock had previously closed at GBX 14.55 ($0.19).

Creo Medical Group Stock Down 1.8 %

The stock’s fifty day moving average price is GBX 18.66 and its 200 day moving average price is GBX 26.89. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96. The stock has a market cap of £50.65 million, a P/E ratio of -237.50 and a beta of 0.86.

Insiders Place Their Bets

In other Creo Medical Group news, insider Richard John Rees purchased 98,000 shares of Creo Medical Group stock in a transaction that occurred on Thursday, October 24th. The shares were bought at an average price of GBX 20 ($0.26) per share, for a total transaction of £19,600 ($25,041.52). Also, insider Kevin Crofton bought 2,916,666 shares of Creo Medical Group stock in a transaction dated Monday, October 21st. The shares were acquired at an average cost of GBX 24 ($0.31) per share, for a total transaction of £699,999.84 ($894,339.90). Insiders own 22.43% of the company’s stock.

About Creo Medical Group

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.